Login to Your Account

Avanir, AstraZeneca: 'Next Step' In Perpetual War On Cholesterol

By Randall Osborne

Monday, July 18, 2005

In late December 2003, when Pfizer Inc. agreed to buy out Esperion Therapeutics Inc. for $1.3 billion - $35 per share, which amounted to a 54 percent premium to the average closing price during the previous 20 days - the pharmaceutical giant paid big for an opportunity that seemed even bigger.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription